ReDrugBC

Novel therapeutic approaches, based on drug repurposing, for high risk non muscle invasive bladder cancer driven by patients’ proteomic signatures

Publications

Frantzi M, Latosinska A, Mokou M, Mischak H, Vlahou A. “Drug repurposing in oncology”, Lancet Oncol. 2020 Dec;21(12):e543.
doi: 10.1016/S1470-2045(20)30610-0.

Mokou M, Lygirou V, Angelioudaki I, Paschalidis N, Stroggilos R, Frantzi M, Latosinska A, Bamias A, Hoffmann MJ, Mischak H, Vlahou A. “A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients' Omics Signatures”, Cancers (Basel). 2020; 12(12):3519. doi: 10.3390/cancers12123519.

Preprints

Stroggilos R, Frantzi M, Zoidakis J, Mavrogeorgis E, Mokou M, Roubelakis MG, Mischak H, Vlahou A. “Gene expression and coexpression alterations marking evolution of bladder cancer”, medRxiv 2021.06.15.21258890.
doi: https://doi.org/10.1101/2021.06.15.21258890

Conferences/Seminars

Mokou M. “Tumor therapy in urinary bladder cancer”, Leipziger interaktives Nephrologie-Seminar LINS 2021 on Multi-omics in Clinical Application, 11-12 September 2021, Oral presentation

Mokou M, Lygirou V, Angelioudaki I, Paschalidis N, Stroggilos R, Frantzi M, Latosinska A, Hoffmann M, Mischak H, Vlahou A. “Drug repurposing of bladder cancer driven by patients’ proteomic signatures", 18th Meeting of the IBCN Saturday, October 17th, 2020 Virtual Meeting, Oral presentation

Leipziger interaktives Nephrologie-Seminar LINS 2021

2022©

ReDrugBC is a Marie Sklodowska Curie Actions (MSCA) Individual Fellowship programme funded by the European Commission (H2020-MSCA-IF-2019, Grant agreement ID: 898260).